Disease modifying treatments (DMT’s) for dementia are on the horizon.

On 19 May 2021, NHS South East Clinical Delivery and Networks held a webinar to discuss the potential impact of DMT’s for Alzheimer’s disease on South East clinical pathways.

The webinar aimed to:

• Share recent DMT trial results
• Discus potential impact on the clinical pathway
• Raise awareness of the opportunities and challenges involved in DMT delivery

The webinar can be watched below and a summary report here.

Subsequent to our webinar on 7 June 2021, the FDA approved Aducanumab for use in Alzheimer’s disease in the United States. In the UK the MHRA and NICE are considering a UK approach.

The horizon has come one step closer.